keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis, remission

keyword
https://www.readbyqxmd.com/read/29214695/psoriasis-improvement-after-gastric-bandage-in-a-patient-partial-responder-to-infliximab
#1
Giulia Odorici, Andrea Conti
Patients overweight or obese have more severe psoriasis than normal weight patients. Sometimes the excessive weight is related to a lack of efficacy of systemic treatment. We report a case of a psoriatic patient that experienced a dramatic improvement of psoriasis after weight loss surgery by gastric bandage. The great weight loss was accompanied by an effectiveness gain of response to infliximab. The mechanism responsible for this association is not certain, but it is probably multifactorial, involving genetic, environmental and immune-mediated factors...
December 7, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/29196889/durable-resolution-of-severe-psoriasis-in-a-patient-treated-with-pentostatin-for-hairy-cell-leukemia-a-case-report
#2
Tamim Alsuliman, Kaiss Lassoued, Maifa Belghoul, Karima Debbache, Bachra Choufi
INTRODUCTION: Pentostatin (2'-deoxycoformycin) and cladribine (2-chlorodeoxyadenosine) are adenosine analogues widely used to treat lymphoid malignancies, mainly hairy cell leukemia (HCL). Oral or parenteral adenosine analogues have been also used as immunomodulatory agents in multiple sclerosis and in acute graft-versus-host disease. CASE REPORT: Here, we report the case of a 43-year-old patient with a history of extensive psoriasis who later developed HCL. RESULTS: The patient had achieved complete remission of both psoriasis and HCL after receiving intravenous infusions of pentostatin...
December 1, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29142032/minimal-disease-activity-as-a-treatment-target-in-psoriatic-arthritis-a-review-of-the-literature
#3
Laure Gossec, Dennis McGonagle, Tatiana Korotaeva, Ennio Lubrano, Eugenio de Miguel, Mikkel Østergaard, Frank Behrens
As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target. Recent recommendations propose aiming for remission or low disease activity; however, a consensual definition of remission is lacking. A state of minimal disease activity (MDA) has been established and is defined by low activity assessed by tender/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity visual analog scale, and functional evaluation by Health Assessment Questionnaire...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29080861/ideal-target-for-psoriatic-arthritis-comparison-of-remission-and-low-disease-activity-states-in-a-real-life-cohort
#4
Leonieke J J van Mens, Marleen G H van de Sande, Arno W R van Kuijk, Dominique Baeten, Laura C Coates
BACKGROUND: Psoriatic arthritis (PsA) recommendations state that the target of treatment should be remission or low disease activity (LDA). We used a real-life dataset to compare different potential targets. METHODS: 250 patients with PsA considered in an acceptable disease state according to their rheumatologist were included. Targets for remission were the Disease Activity Index for Psoriatic Arthritis (DAPSA) and clinical DAPSA (cDAPSA) remission (≤4), very low disease activity (VLDA) and Psoriatic Arthritis Disease Activity Score ≤1...
October 28, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29072309/hla-cw6-and-psoriasis
#5
REVIEW
L Chen, T F Tsai
Psoriasis is a multifactorial disease with a strong genetic background. HLA-Cw6 is one of the most strongly associated psoriasis susceptibility allele. It is repeatedly observed to affect disease course, phenotypic features, severity, comorbidities, and treatment outcomes. To the best of our knowledge, the roles of HLA-Cw6 in psoriasis have not yet been thoroughly reviewed. The worldwide frequency of HLA-Cw6 allele varies greatly, with HLA-Cw6 allele frequency being generally higher in Caucasians compared to Asians...
October 26, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29058948/pace-study-real-life-pasi-100-response-with-biological-agents-in-moderate-severe-psoriasis
#6
Carlo Giovanni Carrera, Paolo Dapavo, Piergiorgio Malagoli, Luigi Naldi, Luisa Arancio, Francesca Gaiani, Colin Gerard Egan, Marco Di Mercurio, Angelo Cattaneo
BACKGROUND: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. OBJECTIVE: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. METHODS: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of PASI90/100 response and time taken to achieve PASI90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI100 response...
October 23, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29035933/psoriatic-arthritis-new-evidence-for-old-concepts
#7
Enrique R Soriano, Josefina Marin, Maria L Acosta-Felquer
PURPOSE OF REVIEW: The review gives an updated overview of some of the new concepts in the management of psoriatic arthritis (PsA): early diagnosis, remission as an objective, treat-to-target, and treatment guidelines. RECENT FINDINGS: Early diagnosis, targeting remission as part of a treatment strategy, and new guidelines providing evidence-based support to these concepts are main topics in recent publications. SUMMARY: Dermatologists and rheumatologists should work together to reduce the number of patients remaining undiagnosed, and the time to do so...
October 13, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28933275/a-case-of-inappropriate-self-medication-compounded-with-prescribing-vis-%C3%A3-vis-dispensing-errors-and-the-hazardous-consequence
#8
Sukalyan Saha Roy, Anupam Roy, Ranjita Santra Dhali, Chiranjib Bagchi, Gautam Banerjee, Santanu K Tripathi
INTRODUCTION Dispensing error, a type of medication error, is not infrequent but seldom reported. Self-medication behavior appears to be a commonplace. And when it is ignorant it may prove dangerous. We report here a case of acute vesico-bullous eruptions from methotrexate in a patient of psoriasis who indulged in self-medication and was wrongfully dispensed higher doses of methotrexate. CASE DESCRIPTION A 50-year-old gentleman presented to the dermatology OPD with erythematous, vesico-bullar lesions spread all over the body including both limbs and scalp, with oral mucosal involvement without any history of fever...
September 19, 2017: Current Drug Safety
https://www.readbyqxmd.com/read/28932788/ustekinumab-induced-remission-of-recalcitrant-guttate-psoriasis-a-case-series
#9
Grace C Brummer, Jason E Hawkes, Kristina Callis Duffin
No abstract text is available yet for this article.
September 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28903122/impact-of-ixekizumab-treatment-on-depressive-symptoms-and-systemic-inflammation-in-patients-with-moderate-to-severe-psoriasis-an-integrated-analysis-of-three-phase-3-clinical-studies
#10
Christopher E M Griffiths, Maurizio Fava, Andrew H Miller, James Russell, Susan G Ball, Wen Xu, Nayan Acharya, Mark Hyman Rapaport
BACKGROUND: Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, was evaluated in patients with moderate-to-severe plaque psoriasis (psoriasis) and depressive symptoms that were at least moderately severe. METHODS: Data were integrated from 3 randomized, double-blind, controlled phase 3 trials. At baseline and week 12, depressive symptoms and inflammation were assessed by the 16-item Quick Inventory of Depressive Symptomology - Self-Report (QIDS-SR16) and by a high-sensitivity assay of serum C-reactive protein (hsCRP), respectively...
2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28735569/treatment-of-moderate-to-severe-psoriasis-with-high-dose-450-mg-secukinumab-case-reports-of-off-label-use
#11
Jennifer Beecker, Jiyeh Joo
Treatment of moderate to severe psoriasis often requires systemic therapy, including biologics. Partial response to biologics and relapses are commonly managed with dose escalation. Secukinumab is a relatively new biologic that is currently used to treat moderate to severe psoriasis. There has been no literature published on dose escalation of secukinumab. This article describes the off-label use of a higher dose of secukinumab (450 mg every 4 weeks) instead of the standard dosing (300 mg every 4 weeks) in 2 patients with moderate to severe psoriasis...
July 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28665918/topical-corticosteroids-or-vitamin-d-analogues-for-plaque-psoriasis
#12
Soledad Venegas-Iribarren, Romina Andino
Psoriasis is a frequent chronic inflammatory disease. The plaque variant being its most common form of presentation. Although there is still no cure, treatment alternatives that induce remission and reduce lesions are available. Topical therapies, particularly corticosteroids and vitamin D analogues, are considered effective, but it is still not clear which would be the best alternative. To answer this question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others...
June 27, 2017: Medwave
https://www.readbyqxmd.com/read/28664281/-psoriatic-arthritis-current-therapeutic-standards
#13
REVIEW
M Köhm, F Behrens
Psoriatic arthritis (PsA) is a heterogeneous immune-mediated disease that usually involves the skin and joints but can also affect the entheses, spine and other extra-articular structures. Furthermore, it can be coupled with associated comorbidities. The selection of a patient-oriented and effective therapy is based on the extent of various manifestations of the disease as well as further influencing factors. Various recommendations for selection and control are available for deciding on a suitable treatment...
June 29, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28604055/deciphering-the-mechanism-of-action-of-wrightia-tinctoria-for-psoriasis-based-on-systems-pharmacology-approach
#14
Sudharsana Sundarrajan, Sajitha Lulu, Mohanapriya Arumugam
OBJECTIVE: Psoriasis is a chronic immune-mediated disorder of the skin. The disease manifests itself with red or silvery scaly plaques distributing over the lower back, scalp, and extensor aspects of limbs. Several medications are available for the treatment of psoriasis; however, high rates of remission and side-effects still persist as a major concern. Siddha, one of the traditional systems of Indian medicine offers cure to many dermatological conditions, including psoriasis. The oil prepared from the leaves of Wrightia tinctoria is prescribed by many healers for the treatment of psoriasis...
November 2017: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
https://www.readbyqxmd.com/read/28552671/morbid-obesity-and-psoriasis-disease-remission-after-laparoscopic-sleeve-gastrectomy
#15
Graziella Babino, Alessandro Giunta, Luca Bianchi, Maria Esposito
Psoriasis is more frequent and severe in populations with obesity, and both have been associated with a higher cardiovascular risk. Recent studies suggest that weight loss may improve psoriasis and metabolic comorbidities in individuals with obesity. We present a case of a female patient affected by psoriasis, morbid obesity and other metabolic comorbidities, who experienced dramatic improvement in skin and joint symptoms and metabolic parameters after weight loss surgery with sleeve gastrectomy.
May 25, 2017: Obesity Research & Clinical Practice
https://www.readbyqxmd.com/read/28547750/management-of-long-term-therapy-with-biological-drugs-in-psoriatic-patients-with-latent-tuberculosis-infection-in-real-life-setting
#16
Andrea Conti, Stefano Piaserico, Paolo Gisondi, Giulia Odorici, Giovanna Galdo, Claudia Lasagni, Giovanni Pellacani
Psoriatic patients with latent tuberculosis infection (LTBI) need a prophylaxis before starting a treatment with biological drugs. The aim of this study is to investigate the safety and efficacy of prophylaxis of LTBI in psoriatic patients receiving long-term biological drugs. The study included 56 patients (42 male and 14 female) affected by moderate-to-severe psoriasis (mean PASI: 12.8 ± 6.9 SD) treated with anti-TNF-α and/or anti IL 12, 23 and/or anti-CD11 drugs with a diagnosis of LTBI. LTBI diagnosis was based on tuberculin skin test and/or QuantiFERON TB Gold test positivity and chest X-ray suggestive, without clinical, or microbiological evidence of active disease...
September 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28532819/il-23-th17-targeted-therapies-in-sapho-syndrome-a-case-series
#17
Daniel Wendling, François Aubin, Frank Verhoeven, Clément Prati
SAPHO syndrome is a rare entity with skin and rheumatologic inflammatory presentation. The treatment is not standardized, and in case of inadequate response to anti-inflammatory drugs, the use of anti-TNF or anti-IL-1 biologic treatments has been reported. The IL-23/Th17 axis may be involved in SAPHO syndrome. We report the results of six courses of IL-23 and IL-17 targeted therapies (3 ustekinumab and 3 secukinumab) in patients with SAPHO syndrome unresponsive to previous treatments (csDMARDs and bDMARDs)...
December 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28452721/ilven-complete-remission-after-administration-of-topical-corticosteroid-case-review
#18
U Wollina, G Tchernev
Inflammatory linear verrucous epidermal nevus (ILVEN) is a relatively rare disorder with an onset at early age, consisting of pruritic linear papules and/or plaques and histologic features resembling psoriasis or lichenoid dermatitis. The disease is a version of mosaicism caused by somatic mutations. ILVEN belongs to the heterogeneous group of congenital hamartomas of embryonal ectodermal origin, as a variant of verrucous epidermal nevus, representing approximately 5% of all epidermal nevi, with predominance in females and with general therapeutic resistance...
February 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28436109/efficiency-of-ustekinumab-in-crohn-s-disease-with-severe-psoriasiform-rash-induced-by-biotherapies-in-an-adolescent
#19
Valérie Bertrand, Abdelaziz El Haite, Delphine Carré
Ustekinumab is approved for the treatment of psoriasis in adolescents and for the treatment of moderate to severe Crohn's disease (CD) in adults, but data are lacking in pediatric CD. We report a case of severe psoriasis induced by biotherapies in an adolescent with CD that improved after switching to ustekinumab (90 mg at weeks 0, 2, and 4 and then every 8 weeks). The patient had not experienced CD relapse after 1 year of follow-up. Ustekinumab can be an alternative therapy for psoriasis induced by biotherapies when conventional treatment fails and can maintain remission of CD...
April 23, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28408798/an-open-randomized-active-controlled-clinical-trial-with-low-dose-ska-cytokines-versus-dmards-evaluating-low-disease-activity-maintenance-in-patients-with-rheumatoid-arthritis
#20
RANDOMIZED CONTROLLED TRIAL
L S Martin-Martin, F Giovannangeli, E Bizzi, U Massafra, E Ballanti, M Cassol, A Migliore
BACKGROUND: Biologic agents are currently the strongest immunosuppressive drugs able to induce remission in rheumatoid arthritis (RA). One of the objectives of the medical scientific community now is how to maintain remission or low disease activity (LDA). The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy...
2017: Drug Design, Development and Therapy
keyword
keyword
108076
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"